Glaxo Inc. v. Novopharm Ltd.
United States Court of Appeals for the Federal Circuit
52 F.3d 1043, 34 U.S.P.Q.2d 1565 (1995)
Facts
Derek Crookes made a form of ranitidine hydrochloride that could be used for pharmaceutical purposes. A patent on the compound was obtained by Crookes’s employer, Glaxo Inc. (plaintiff). Glaxo brought an infringement action against Novopharm Ltd. (defendant) in federal district court. Evidence showed that Glaxo used a process call azeotroping to formulate the compound and that Glaxo officials knew this process to be the best mode of practicing the invention. However, azeotroping was not disclosed in Glaxo’s patent. Novopharm therefore argued that the patent was invalid because it failed to disclose the best mode of practicing the invention, as required by § 112 of the patent statute. The court found in favor of Glaxo because there was no evidence that the original inventor—Crookes himself—had used the azeotroping process. Novopharm appealed to the United States Court of Appeals for the Federal Circuit.
Rule of Law
Issue
Holding and Reasoning (Rich, J.)
What to do next…
Here's why 688,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 43,000 briefs, keyed to 988 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.